Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)

• Company Description    Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.56 Daily Weekly Monthly 20 Day Moving Average: 188,357 shares Shares Outstanding: 18.65 (millions) Market Capitalization: $10.41 (millions) Beta: 3.94 52 Week High: $3.87 52 Week Low: $0.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -42.06% -41.96% 12 Week -62.80% -63.40% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1776 YORKTOWN SUITE 550 - Houston,TX 77056 USA ph: 832-260-0222 fax: - nxl@crescendo-ir.com http://www.nexalin.com

• General Corporate Information    Officers Mark White - Chief Executive Officer and Chief Financial Office Carolyn Shelton - Senior Vice President of Quality; Clinical and Reg Alan Kazden - Director Ben Hu - Director Leslie Bernhard - Director Peer Information Nexalin Technology, Inc. (EVOL) Nexalin Technology, Inc. (RAMP) Nexalin Technology, Inc. (LGTY) Nexalin Technology, Inc. (ALOT) Nexalin Technology, Inc. (CXT) Nexalin Technology, Inc. (TGHI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Technology Services Sector: Business Services CUSIP: 65345B201 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/13/26 Share - Related Items Shares Outstanding: 18.65 Most Recent Split Date: (:1) Beta: 3.94 Market Capitalization: $10.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.07 Price/Cash Flow: - Price / Sales: 66.29 EPS Growth vs. Year Ago Period: 43.48% vs. Previous Quarter: -30.00% Sales Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -74.65% ROE 12/31/25 - - 09/30/25 - -207.46 06/30/25 - -209.20 ROA 12/31/25 - - 09/30/25 - -184.51 06/30/25 - -186.87 Current Ratio 12/31/25 - - 09/30/25 - 13.45 06/30/25 - 10.43 Quick Ratio 12/31/25 - - 09/30/25 - 13.01 06/30/25 - 10.14 Operating Margin 12/31/25 - - 09/30/25 - -5,527.39 06/30/25 - -5,057.14 Net Margin 12/31/25 - - 09/30/25 - -5,527.39 06/30/25 - -5,057.14 Pre-Tax Margin 12/31/25 - - 09/30/25 - -5,527.39 06/30/25 - -5,057.14 Book Value 12/31/25 - - 09/30/25 - 0.27 06/30/25 - 0.35 Inventory Turnover 12/31/25 - - 09/30/25 - 0.28 06/30/25 - 0.33 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©